SCHEMBL20914254

SCHEMBL20914254

Cc1[nH]c2c(-c3ccccc3)c(C#N)nn2c(=O)c1-c1nc2cnccc2o1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DAGLA Q9Y4D2 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4C Q9H3R0 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ F2 P00734 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MDM2 Q00987 1/20 0.33
▸ MAT2A P31153 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.32
▸ MGLL Q99685 1/20 0.32
▸ KDM5A P29375 4/20 0.32
▸ F7 P08709 1/20 0.32
▸ F3 P13726 1/20 0.32
▸ CDK5 Q00535 2/20 0.32
▸ PDGFRA P16234 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837037 0.90 P2RY6 (0.37) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20914318 0.85 RAB9A (0.41) MEN1KMT2APKMTSHRALDH1A1
SCHEMBL20914267 0.83 KDM4E (0.38) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20914308 0.81 MAT2A (0.34) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20913968 0.80 KDM4E (0.34) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20837240 0.80 KMT2A (0.34) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20837038 0.80 ADORA2A (0.34) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20914241 0.80 MEN1 (0.42) MEN1KMT2ACYP1A2CYP2C9PKM
SCHEMBL20931257 0.79 MDM2 (0.38) MEN1KMT2AKDM4CCYP1A2CYP2C9
SCHEMBL20914302 0.78 CDK5 (0.35) MEN1KMT2AKDM4CCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
CN-111212839-A Pyrazolopyrimidinone compounds and uses thereof 艾杜罗生物科技公司 2020-05-29 — — CN disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 DAGLA 4737/4885MEN1 2785/4885KMT2A 3490/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 DAGLA 4737/4885MEN1 2785/4885KMT2A 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback